Unither Pharmaceuticals
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Unither Pharmaceuticals - overview
Established
1993
Location
Paris, -, France
Primary Industry
Pharmaceuticals
About
Unither Pharmaceuticals, headquartered in Paris, France, is engaged in the development and manufacturing of single-dose healthcare products using innovative Blow-Fill-Seal (BFS) technology. Founded in 1993 in Paris, France, Unither Pharmaceuticals specializes in developing and manufacturing liquid healthcare products. The company underwent a significant change in ownership in October 2022 when a consortium, including Parquest Capital, acquired a majority stake from Ardian. CEO Jean-Francois HILAIRE leads the firm, which has completed 6 total deals.
Unither Pharmaceuticals focuses on developing and manufacturing healthcare products, particularly single-dose liquid formulations via Blow-Fill-Seal (BFS) technology. Their product lineup includes eye drops, saline solutions, asthma medications, liquid stick-packs, tablets, and suppositories. These offerings are primarily aimed at pharmaceutical laboratories and generic manufacturers, catering to over 100 countries worldwide and emphasizing patient compliance and healthcare accessibility. In 2023, Unither Pharmaceuticals reported a revenue of EUR 889,662.
50, with an EBITDA of EUR -3,431,984. 80. Looking ahead, Unither Pharmaceuticals plans to launch new products and expand its market presence, specifically targeting China and the United States. The recent Secondary Buyout, which raised EUR 75.
00 mn, will support these initiatives, enhancing their Blow-Fill-Seal product offerings.
Current Investors
Parquest Capital, Equistone Partners Europe, CM-CIC Capital Privé
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.unither-pharma.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Unither Pharmaceuticals - timeline of key events
Unither Pharmaceuticals - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Corporate Carve Out | Completed | Marinomed's Carragelose Business | - | ||||||||
| Private Debt | Completed | Unither Pharmaceuticals | - | ||||||||
| Buyout | Announced | Unither Pharmaceuticals | - | ||||||||
| Add-on | Completed | Nanjing Bai Site in Swiss Pharmaceutical Co., Ltd. | - | ||||||||
| Secondary Buyout | Completed | Unither Pharmaceuticals | - |
Displaying 1 - 5 of 8
Unither Pharmaceuticals - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.